article Open AccessTop 1% cited

Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy

Journal of Clinical Oncology · 2004 · Vol. 22(9) · pp. 1589–1597

Nasser H. Hanna✉(Ontario Institute for Cancer Research)Frances A. Shepherd(Ontario Institute for Cancer Research)Frank V. Fossella(Ontario Institute for Cancer Research)Jose R. Pereira(Ontario Institute for Cancer Research)Filippo de Marinis(Ontario Institute for Cancer Research)Joachim von Pawel(Ontario Institute for Cancer Research)U. Gatzemeier(Ontario Institute for Cancer Research)Thomas Chang Yao Tsao(Ontario Institute for Cancer Research)Miklos Pless(Ontario Institute for Cancer Research)Thomas Müller(Ontario Institute for Cancer Research)Hong-Liang Lim(Ontario Institute for Cancer Research)Christopher E. Desch(Ontario Institute for Cancer Research)Klára Szondy(Ontario Institute for Cancer Research)Radj Gervais(Ontario Institute for Cancer Research)ShaharyarChristian Manegold(Ontario Institute for Cancer Research)Sofia Paul(Ontario Institute for Cancer Research)Paolo Paoletti(Ontario Institute for Cancer Research)Lawrence Einhorn(Ontario Institute for Cancer Research)Paul A. Bunn(Ontario Institute for Cancer Research)

View via DOI Full-text PDF

Abstract

Treatment with pemetrexed resulted in clinically equivalent efficacy outcomes, but with significantly fewer side effects compared with docetaxel in the second-line treatment of patients with advanced NSCLC and should be considered a standard treatment option for second-line NSCLC when available.

Lung Cancer Treatments and Mutations Lung Cancer Diagnosis and Treatment Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisMedicineDocetaxelPemetrexedNeutropeniaInternal medicineLung cancerFebrile neutropeniaChemotherapyRegimenDexamethasone

MeSH terms

PemetrexedDocetaxelAdultAgedAged, 80 and overAntineoplastic AgentsAntineoplastic Agents, PhytogenicCarcinoma, Non-Small-Cell LungFemaleGlutamatesGuanineHumansLung NeoplasmsMaleMiddle Aged

Citations

2,425

FWCI

107.59

field-weighted impact

References

Percentile

100%

vs. same field & year

Citations per year

Cited by

Pretreatment platelet count and neutrophil/lymphocyte ratio are predictive markers for carboplatin plus pemetrexed therapy-induced thrombocytopenia